Skystar’s Chairman and CEO, Mr. Weibing Lu, commented, “Skystar is pleased to launch its new bovine IgG kits in China. Having performed market research with our customers, we anticipate that, the bovine IgG kits, represent an approximate $1.5 million annual revenue opportunity for Skystar, upon full production. The bovine IgG kits will target and will be marketed to both small and medium scale pig farms in China. Following our assessment of the needs of our customers in the farming industry in China, we designed kits that were intended to address the need for a product that treats the most common diseases encountered in pig farming. Skystar will continue to meet the challenge of developing its product lines for the changing needs of China’s animal husbandry industry which continually move forward with modern industrialization and standardization of animal husbandry practices. The Company believes that China’s regulatory environment encouraging new standards of food safety, will support and create opportunities for its overall growth in the near to medium term.”
Skystar’s bovine immunoglobulin G (IgG) kits are comprised of a proprietary formula of vitamin supplements including B1, B2, B6, and niacin in combination with ATP, immune boosting antigen specific transfer factor molecules and five different immunoglobulin (IgG) G antibodies for the prevention and treatment of commonly occurring diseases found in pig farming, including blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease.
When used in this release, the words “intends,” “believes,” “anticipated” and “expects” and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company’s ability to complete the launch of its IgG kits in the anticipated timeframe and to attain the anticipated revenue and market penetration, as well as other related efforts at the Huxian facilities, the Company’s ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company’s ability to realize the anticipated $1.5 million revenue opportunity, the Company’s ability to timely and effectively commercialize any such technologies. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.